Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.
www.marketwatch.com
#Novo #Nordisk #CEO #tells #investors #expect #weightloss #drug #pricing
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
